View Older Stories View More Recent Stories

Dec 17, 2024 08:00AM MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
Dec 17, 2024 06:46AM Merck (MRK) Announces FDA Acceptance of BLA for Clesrovimab
Dec 17, 2024 06:45AM Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV
Dec 16, 2024 04:30PM Merck (MRK) Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab
Dec 16, 2024 04:30PM Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
Dec 16, 2024 06:45AM Merck's (MRK) KEYTRUDA Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment
Dec 16, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Re
Dec 13, 2024 07:06AM Merck (MRK) Receives Positive EU CHMP Opinion for WELIREG
Dec 13, 2024 07:05AM Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated
Dec 11, 2024 10:22AM LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
Dec 9, 2024 06:49AM Merck (MRK) Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Dec 9, 2024 06:45AM Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Dec 8, 2024 03:00PM Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse L
Dec 5, 2024 01:45PM Merck Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025
Dec 5, 2024 06:46AM Merck (MRK) and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study Evaluating LAGEVRIO for the Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024 06:45AM Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
Dec 3, 2024 06:45AM Merck (MRK) Granted FDA Breakthrough Therapy Designation to Sacituzumab Tirumotecan
Dec 3, 2024 06:45AM FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Ca
Nov 26, 2024 06:45AM Merck to Participate in the Citi 2024 Global Healthcare Conference
Nov 25, 2024 06:46AM Merck (MRK) Announces Phase 3 ZENITH Trial Evaluating WINREVAIR Met Primary Endpoint at Interim Analysis
Nov 25, 2024 06:45AM Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
Nov 22, 2024 04:17PM Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Nov 22, 2024 07:15AM Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Nov 22, 2024 06:46AM Merck's (MRK) WELIREG Approved in China for Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Nov 22, 2024 06:45AM Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Nov 22, 2024 06:34AM Merck (MRK) Announces Surendralal Karsanbhai Elected to Board of Directors
Nov 22, 2024 06:30AM Surendralal Karsanbhai Elected to Merck Board of Directors
Nov 21, 2024 06:45AM Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
Nov 19, 2024 12:22PM Merck Announces First-Quarter 2025 Dividend
Nov 19, 2024 06:45AM Merck (MRK) Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Nov 19, 2024 06:45AM Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Nov 15, 2024 07:16AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemo as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid MPM
Nov 15, 2024 07:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MP
Nov 14, 2024 07:15AM Merck to Participate in the Jefferies London Healthcare Conference
Nov 14, 2024 06:45AM Merck (MRK) Enters into Exclusive Global License for LM-299
Nov 14, 2024 06:45AM Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Nov 12, 2024 06:45AM Merck (MRK) reports KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo
Nov 12, 2024 06:45AM KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Ple
Nov 12, 2024 03:00AM Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
Nov 6, 2024 06:45AM Merck to Participate in the UBS Global Healthcare Conference
Oct 31, 2024 06:30AM Merck Announces Third-Quarter 2024 Financial Results
Oct 29, 2024 08:01AM MilliporeSigma Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies
Oct 28, 2024 06:46AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
Oct 28, 2024 06:45AM Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types
Oct 24, 2024 06:45AM Merck's (MRK) KEYTRUDA Receives 30th Approval From EU Commission With Two New Indications in Gynecologic Cancers
Oct 24, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
Oct 23, 2024 07:58PM CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
Oct 21, 2024 05:59AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 21, 2024 05:58AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 19, 2024 05:09PM Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Wee
View More Recent Stories View Older Stories